Undaunted Bio
Seed-stage biotechnology company focused on repurposing existing drugs for neuropathic pain. Uses a clinically informed, AI-driven, network-medicine approach combined with cell-based models and medicinal chemistry to interrogate mechanism of action, reformulate a lead repurposed candidate into an oral thin film, and advance toward IND-enabling studies and human trials via the FDA 505(b)(2) pathway.
Industries
N/A
Products
Repurposed drug reformulated as oral thin film for trigeminal neuralgia (lead candidate)
A repurposed clinical-stage compound being reformulated into an oral thin film dosage form for treatment of trigeminal neuralgia and other neuropathic pain indications; currently pre-IND and being developed via the FDA 505(b)(2) pathway.
Repurposed drug reformulated as oral thin film for trigeminal neuralgia (lead candidate)
A repurposed clinical-stage compound being reformulated into an oral thin film dosage form for treatment of trigeminal neuralgia and other neuropathic pain indications; currently pre-IND and being developed via the FDA 505(b)(2) pathway.
Services
Partnership and investor engagement
Preparation and sharing of investor materials and engagement with advisors and collaborators to support seed fundraising and development milestones.
Partnership and investor engagement
Preparation and sharing of investor materials and engagement with advisors and collaborators to support seed fundraising and development milestones.
Expertise Areas
- Drug repurposing for neuropathic pain
- AI-driven drug discovery and knowledge-graph analytics
- Preclinical model development for neuropathic pain
- Formulation development (oral thin film)
Key Technologies
- Large language models (LLMs)
- Knowledge graphs
- Network medicine / graph-based analysis
- Cell-based neuropathic pain assays